Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$10.81 - $17.96 $78,167 - $129,868
-7,231 Reduced 6.38%
106,093 $1.41 Million
Q4 2023

Feb 06, 2024

BUY
$8.84 - $18.7 $1 Million - $2.12 Million
113,324 New
113,324 $1.58 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $368M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Vestmark Advisory Solutions, Inc. Portfolio

Follow Vestmark Advisory Solutions, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestmark Advisory Solutions, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vestmark Advisory Solutions, Inc. with notifications on news.